After decades of antipsychotic drugs, a new FDA-approved treatment for schizophrenia targets a different brain system—with ...

Medically reviewed by Michael MacIntyre, MD Schizophrenia medication falls under two main categories: older, first-generation ...

Computational neuroscience contributes to our understanding of complex diseases. Here, Rolls and colleagues review several models of schizophrenia, focusing on those that include attractor networks.

People with cannabis use disorder show signs of altered dopamine activity in the brain that mirror patterns seen in psychosis, according to a new brain imaging study published in JAMA Psychiatry.

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to schizophrenia treatment. The Food and Drug Administration approved it Thursday.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach. By Ellen Barry and Christina Jewett The Food and Drug Administration on ...

For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it causes brutal side effects for others. An antipsychotic drug approved last ...

People living with schizophrenia will soon have a new and potentially groundbreaking treatment available. It’s called Cobenfy, and it’s the first new drug for the mental health condition to be ...

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia.The drug targets cholinergic receptors as opposed ...

On Sept. 26, for the first time in nearly 30 years, the U.S. Food and Drug Administration approved a new oral drug, Cobenfy, developed by Bristol Myers Squibb, to treat schizophrenia. Schizophrenia is ...

An estimated one-quarter to one-third of people with schizophrenia have symptoms that don’t improve with traditional treatments. This is known as treatment resistance.

N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...